Similarly acting agents from Merck & Co and Altimmune aim to improve NAFLD, with mixed results.
Pfizer keeps declining, but it is not the only pandemic player to suffer.
The company’s value is cut in half as mid-stage data prove a let-down.
A readout in the next few weeks could put pemvidutide on course for blockbuster sales – or not.
Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.